Infantile Hemangioma - CHU Sainte-Justine - SAAC

More documents

Recommendations

Info

Topical Beta Blockers• 20 articles since February 2010: ~175 patientsreported• Nearly all retrospective: Largest series- 73 patients• Mostly timolol ophthalmic solution but 2 reportsused compounded propranolol• Varied concentrations and frequency• Timolol – most 0.5% GFS formulation but others• Duration usually 3 mos or moreChakkittakandiyil A et al. Pediatr Dermatol. 2012 ;29:28-31
Topical Beta-Blockers:Experience in past 2.5 years• Encouraging results• Eyelid lesions do particularly well• Self-selection for more superficial and smallerhemangiomas• Well-tolerated: No significant toxicity reportedto date• Relatively inexpensive• Should primary care physicians use as initial Rx(with or without referral)?
Page 1 and 2: Infantile Hemangiomas:Approach and
Page 3 and 4: Overview• Which hemangiomas need
Page 5 and 6: How do we decidewhich hemangiomasto
Page 7 and 8: Risk of Segmentals• Segmental hem
Page 9 and 10: Residual skin changes inuntreated h
Page 11 and 12: Very Early Growth:Birth 1 year 2yea
Page 13 and 14: Very Early Growth:Study usingparent
Page 15 and 16: Timing of Initiation of Treatment~1
Page 17 and 18: Reevaluationat age 3 to 4 years•
Page 19 and 20: Propranolol as RxLéauté-Labrèze
Page 21 and 22: Results of Systematic Review• Res
Page 23 and 24: Propranolol ConsensusGuidelinesDrol
Page 25 and 26: Monitoring - All Patients• The pe
Page 27 and 28: Caveat• This information is based
Page 29: What about TopicalBeta-Blockers?

Infantile Hemangioma - CHU Sainte-Justine - SAAC

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?